Results 21 to 30 of about 57,995 (263)

Therapeutic applications of octreotide in pediatric patients

The Saudi Journal of Gastroenterology, 2012
Background/Aim: We report our experience with the use of octreotide as primary or adjunctive therapy in children with various gastrointestinal disorders.
Abdulrahman Al-Hussaini, Decker Butzner
doaj   +1 more source

Somatostatin subtype-2 receptor-targeted metal-based anticancer complexes [PDF]

, 2012
Conjugates of a dicarba analogue of octreotide, a potent somatostatin agonist whose receptors are overexpressed on tumor cells, with [PtCl 2(dap)] (dap = 1-(carboxylic acid)-1,2-diaminoethane) (3), [(η 6-bip)Os(4-CO 2-pico)Cl] (bip = biphenyl, pico ...
Alejandro González-Cantó, Algueró B., Anna Massaguer, Barragán F., Barragán F., Bauer W., Carlos González, Cascini G. L., Casini A., Chaplin A. B., Charvat T. T., de Jong M., Deshmukh M. V., Dirscherl G., Dolors Carrion-Salip, D’Addona D., Fischer R., Flavia Barragán, Gariepy J., Gasser G., Gianferrara T., Gossens C., Gross A., Hodson E., Hornick C. A., Hsieh H.-P., Huang C. M., Irene Gómez-Pinto, Jakupec M. A., Jakupec M. A., Janecka A., Jennerwein M., Koradi R., Kostrhunova H., Kostrhunova H., Levina A., Liu H.-K., Marchán V., Marchán V., Melacini G., Metzler-Nolte N., Mezo G., Moradell S., Moreno V., Morris R. E., Mukhopadhyay S., Novakova O., Okarvi S. M., Peacock A. F. A., Peacock A. F. A., Peacock A. F. A., Peindy N’Dongo H. W., Peter J. Sadler, Pizarro A. M., Puckett C. A., Rademaker-Lakhai J. M., Rafael de Llorens, Reubi J. C., Reubi J. C., Schaer J. C., Singh S. K., Splith K., Sun L.-C., Süss-Fink G., van Rijt S. H., van Rijt S. H., van Rijt S. H., van Rijt S. H., Vicente Marchán, Virtudes Moreno, Wang F., Wang F., Watson J. C., Wheate N. J., Wynants C., Wynants C., Zaccaro L., Zhang J., Zhang Y.   +78 more
core   +5 more sources

The effect of preoperative short-term octreotide treatment to surgery in thyrotropin-secreting pituitary adenomas: a retrospective cohort study

BMC Endocrine Disorders, 2023
Background To prevent thyroid storm and ensure surgical safety, it is imperative to regulate excessive thyroid hormone levels in patients with thyrotropin-secreting pituitary adenomas (TSHoma) prior to surgery.
Runsheng Zhao, Kaiyu Fan, Weiqing Wan
doaj   +1 more source

The effect of SRIH-14 or octreotide on the morphological characteristics of adrenal medulla using newcast [PDF]

Archives of Biological Sciences, 2010
The effects of chronic treatments with either SRIH-14 or octreotide on the adrenal medulla of male Wistar rats were examined. Adult males received subcutaneous (s.c.) injections of 20 μg/100 g body weight of either SRIH-14 or octreotide twice a day for ...
Trifunović Svetlana, Filipović B., Ajdžanović V., Manojlović-Stojanoski Milica, Nestorović Nataša, Sekulić Milka, Milošević Verica   +6 more
doaj   +1 more source

Pharmacological Treatment of Postprandial Reductions in Blood Pressure : A Systematic Review [PDF]

, 2015
Funded by The Dunhill Medical Trust.
Alam, Aronow, Freeman, Gentilcore, Heseltine, Heseltine, Hirayama, Jansen, Jansen, Jansen, Jansen, Jian, Jones, Jones, Lenders, Lipsitz, Lipsitz, Moher, O'Donovan, Onrot, Potter, Rakic, Russo, Sawynok, Shibao, Vaitkevicius, Visvanathan, Vloet, Vloet   +28 more
core   +1 more source

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.

World Journal of Gastroenterology, 2015
AIM To review literature on efficacy and safety of octreotide-long-acting repeatable (LAR) used at doses higher than the Food and Drug Administration (FDA)-approved 30 mg/mo for treatment of neuroendocrine tumors (NETs).
M. Broder, D. Beenhouwer, J. Strosberg, M. Neary, D. Cherepanov   +4 more
semanticscholar   +1 more source

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]

, 2019
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger, Jann, Henning, Kayser, Antonin, Roderburg, Christoph, Stueven, Anna Kathrin, Tacke, Frank, Wetz, Christoph, Wiedenmann, Bertram, Wree, Alexander   +8 more
core   +1 more source

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

Trials, 2011
Background Polycystic liver disease (PLD) is defined as having more than 20 liver cysts and can present as a severe and disabling condition. Most symptoms are caused by the mass effect of the liver size and include abdominal pain and distension.
Chrispijn Melissa, Drenth Joost PH
doaj   +1 more source

Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor. [PDF]

, 2012
Pancreatic neuroendocrine tumors (PNETs) are relatively rare tumors that arise in the endocrine cells of the pancreas. Historically, somatostatin analogues have been used in this disease primarily for symptom control and, to a limited extent, disease ...
Devata, Sumana, Kim, Edward J
core   +2 more sources

Use of Octreotide in the Acute Management of Bleeding Esophageal Varices

Canadian Journal of Gastroenterology, 1997
Acute hemorrhage from esophageal varices is a medical emergency; despite early diagnosis and treatment the associated hospital mortality remains high.
Daniel C Sadowski
doaj   +1 more source